Details of the Drug Reposition

General Information of This Drug (ID: DMP6B59)

• Drug Name: Ocaperidone (DMP6B59)
• Synonyms: Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; Ocaperidona; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

5 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Pancreatic cancer	DISJC981	2C10	Phase 2	[1]
Type-2 diabetes	DIS3X247	5A11	Phase 2	[2]
Schizophrenia	DISSRV2N	6A20	Phase 2	[3]
Schizoaffective disorder	DISLBW6B	6A21	Phase 2	[3]
Idiopathic pulmonary fibrosis	DISZGA69	CB03.4	Phase 2	[2]

1 Phase 1b Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Diabetic nephropathy	DIS2FCCT	GB61.Z	Phase 1b	[2]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 46).